紫杉醇-姜黄素介孔SiO_2/脂质复合递药系统体外释药研究

In vitro release study of paclitaxel and curcumin co-encapsulated mesoporous silica/lipid compound drug delivery system

为了考察自制紫杉醇-姜黄素介孔SiO_2/脂质复合递药系统的体外释药行为,建立高效液相色谱法同时检测紫杉醇-姜黄素浓度;筛选适当增溶剂增加紫杉醇-姜黄素溶解度;反透析法考察各药物组的体外释药行为,绘制紫杉醇-姜黄素累积释药曲线并进行释药模型拟合。结果显示,不同药物组中紫杉醇-姜黄素释药行为表现出一定差异性,两种药物单药组累积释药量均高于混合组,自制递药系统累积释药量均高于裸药组。但紫杉醇不同递药系统组累积释药量由高到低分别为:MSNs>PLMSNs>LMSNs,姜黄素不同递药系统组累积释药量由高到低分别为:LMSNs>PLMSNs>MSNs。此外,PLMSNs组中紫杉醇-姜黄素释药行为均符合Hixon-Crowell释药模型。

To investigate the in vitro release of paclitaxel and curcumin in mesoporous silica/lipid compound drug delivery sys- tem, concentrations of paclitaxel and curcumin were analyzed by HPLC simultaneously. Appropriate solubilizing agent was selected to fit the sink condition. The in vitro release study of six groups including paclitaxel group, curcumin group, paclitaxel/curcumin mix- ture group, MSNs group, LMSNs group and PLMSNs group were performed by reverse dialysis method. Cumulative drug release curves were drawn and release model was fitted then. Both paclitaxel and curcumin single drug group exhibited higher cumulative re- lease amount than paclitaxel/curcumin mixture group. Cumulative release amount of drug delivery system groups was higher than that of drug powder groups. Accumulative release arrangement of paclitaxel from high to low was ： MSNs 〉 PLMSNs 〉 LMSNs, while the accumulative release arrangement of curcumin from high to low was ： LMSNs 〉 PLMSNs 〉 MSNs. Meanwhile, drug release behaviors of paclitaxel and curcumin in PLMSNs group were all in accordance with the Hixon - Crowell release model with high fitting degree. Key words：paclitaxel ; curcumin ; mesoporous silica / lipid compound drug delivery system ; in vitro release